Talsaclidine
Alternative Names: Talsaclidine fumarate; WAL-2014; WAL-2014FULatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Pharmacia Corporation
- Class Nootropics
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 06 Apr 2001 Discontinued-II for Alzheimer's disease in USA, Canada, Australia, New Zealand, France, Germany, and the UK (PO, capsule)
- 30 Apr 1997 Phase-I clinical trials for Alzheimer's disease in USA (PO)
- 22 Jan 1997 Phase-II clinical trials for Alzheimer's disease in Germany (PO)